Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Promethera Biosciences Opens the French Part of its Clinical Trial in Cell Therapy

Published: Thursday, February 28, 2013
Last Updated: Thursday, February 28, 2013
Bookmark and Share
Promethera successfully administers Promethera® HepaStem in an adolescent suffering from an Urea Cycle Disorder at Hospital Jeanne de Flandre, Lille, France.

Promethera Biosciences has announced that it has successfully treated a patient with liver progenitor cells enrolled in its Phase I/II trial. The intervention was performed in January 2013 at the University Children’s Hospital Jeanne de Flandre in Lille, France.

Promethera Biosciences is currently conducting a Phase I/II clinical study involving Crigler-Najjar syndrome and Urea Cycle Disorders patients that has been approved by FAMHP (Belgian Authorities), MHRA (British Authorities), ANSM (French Authorities) and ISS (Italian Authorities).

This patient is the first one treated in France and the first one treated outside of Belgium where the study was launched.

The trial, a prospective, open label, multicenter Phase I/II study is a dose escalation study designed to evaluate the safety and the preliminary efficacy of Promethera® HepaStem in Urea Cycle Disorders and Crigler-Najjar Syndrome pediatric patients.

These diseases are extremely rare. Most young patients have only limited therapeutic options and may die at an early stage.

On January 25, 2013, a 14-year-old adolescent suffering from Ornithine Transcarbamylase Deficiency (OTCD, one of the Urea Cycle Disorders) was treated with liver progenitor cells. The patient is the first to have been treated in France.

The administration of the cells took place at Hospital Jeanne de Flandre in Lille, France. It was coordinated by the reference center of Inherited Metabolic Diseases of Child and Adulthood of Dr. Dries Dobbelaere in collaboration with the Paediatric Clinical Investigation Center of Prof. Frederic Gottrand.

The treatment was successfully applied over three days. The cell formulation was performed both on clinical site in Promethera’s mobile formulation unit and at the premises in Mont-Saint-Guibert, Belgium.

The patient was discharged in good condition and is doing well. He is being closely monitored by Dr Dobbelaere’s medical team.

Administration of Promethera® HepaStem was already successfully performed in four more patients at the Cliniques Universitaires Saint-Luc in Brussels, Belgium.

The safety data collected so far supports the good tolerability of Promethera® HepaStem in the phase I/II clinical study and warrants further enrolment of new patients.

“We expect that this innovative treatment will address an important unmet need for physicians and patients. It will improve their quality of life and ease the daily disease management,” says Dr Dries Dobbelaere.

“We are very pleased with the progress of this Phase I/II trial. With the treatment of a patient abroad, using our mobile formulation unit, we have demonstrated the feasibility of such a treatment anywhere in Europe,” says Eric Halioua, co-founder and chief executive officer of Promethera Biosciences.

Professor Etienne Sokal, co-founder of Promethera Biosciences and chief scientific officer, paediatric hepatologist at Cliniques Universitaires, Saint Luc, Belgium and director of UCL’s Cell Therapy Research Lab, Belgium adds: “With this first patient treated outside the founding clinical site, Promethera Biosciences has shown that liver stem cell therapy could become a widely accessible medicinal therapy, which can be applied for all patients in need within their own metabolic treatment center.”

Dr. Beatrice De Vos, chief medical officer of Promethera Biosciences concludes: “A close and profound collaboration between the clinical teams in Brussels, in Lille and at Promethera is the cornerstone of this successful outcome. We are very keen to share this expertise with other centers in Belgium, France, UK and Italy participating in this trial.”

The clinical centers in UK and Italy are preparing to welcome the next patients for this clinical trial.

The major innovation of Promethera® HepaStem is in the simplicity of the treatment - a simple injection into the vein leading to the liver. Promethera® HepaStem could be used to treat a wide variety of liver pathologies.

Thanks to the industrial development, the potential for treating hundreds of patients from a single liver could become a reality.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Promethera® Biosciences Reshapes its Leadership Team
Company announces resignation of Eric Halioua from his post as CEO of Promethera.
Saturday, January 24, 2015
Promethera Appoints Dr John Tchelingerian as the New Chairman of the Board
John Tchelingerian, PhD, a well-recognized biotech entrepreneur, brings scientific, deal making and commercial experience to the team.
Tuesday, December 30, 2014
Promethera Biosciences Raises €25.33 Million in Series C Financial Round
Promethera Biosciences raises €20.33 million in capital and €5 million in loans and subsidies from the Walloon region (Belgium).
Thursday, November 27, 2014
Promethera Receives Approval to Enroll Patients in the Imminent HEP002 Phase IIb/III Clinical Trial
HEP002 trial represents the world’s first Phase IIb/III trial with a stem cell-based medicinal product for the treatment of urea cycle disorders patients.
Thursday, October 16, 2014
Promethera Successfully Enrolls Twenty Patients in its Multicentric Phase I/II Trial
Promethera Biosciences has conducted the trial in Belgium, France, United Kingdom, Italy and Israel, treating twenty patients affected by very rare liver-based metabolic diseases.
Tuesday, November 12, 2013
Promethera Biosciences Treats First Patients with Promethera® HepaStem
Phase I/II study designed to evaluate the ability of liver progenitor cells to restore a missing enzyme function in liver-based metabolic diseases.
Tuesday, May 15, 2012
Scientific News
Gene Therapy Maintains Clotting Factor for Hemophilia Patients
Following a single gene therapy dose, the highest levels of an essential blood clotting factor IX were observed in hemophilia B patients.
Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Combination Therapy Improved Chemoresistance in Ovarian Cancer
The study demonstrates how an existing class of targeted therapies could be used to potentiate the tumor suppression induced by cisplatin.
Gene Therapy for Blistering Skin Disease Shows Promise
Grafting genetically altered skin onto patients’ chronic wounds marks the first time skin-based gene therapy has been demonstrated to be safe and effective in humans.
Alzheimer’s Treatment Moves a Step Closer
Merck scientists have reported the discovery of verubecestat, a structurally unique, orally bioavailable small molecule that has been shown to target the most visible sign of the disease in the brain.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!